TELA News and Press, TELA Bio Inc. From 11/09/22

TELA Bio press release ( NASDAQ: TELA ): Q3 GAAP EPS of -$0.64 misses by $0.02 . Revenue of $11.2M beats by $0.33M . 2022 Financial Guidance We continue to expect full year 2022 revenue to range from $42 million to $45 million vs $42.80M consensus, refl...

MALVERN, Pa., Nov. 09, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's o...

MALVERN, Pa., Nov. 03, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’...

MALVERN, Pa., Oct. 27, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’...

MALVERN, Pa., Oct. 26, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc . (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own ana...

Summary Shares of TELA Bio have fallen by 40% since public offering in 2019. Differentiation for OviTex versus competitors in terms of clinical outcomes and economics could help them transition from niche player to broad provider. GPO wins, especially Premier, should cause sal...

Medical technology company TELA Bio ( NASDAQ: TELA ) has closed an underwritten public offering of 4.6M shares at $8.00 per share for gross proceeds of $36.8M. The offering includes 600K shares sold pursuant to the full exercise of the underwriter's option to purchase...

MALVERN, Pa., Aug. 18, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’...

Save Foods ( SVFD ) -35% on pricing of $4.8M stock offering . Albireo Pharma ( ALBO ) -23% on Q2 earnings release . Tremor International ( TRMR ) -17% on Q2 earnings release . GAN ( GAN ) -17% on Q2 earnings release . Hel...

Tela Bio ( NASDAQ: TELA ) priced an offering of 4M common shares at $8 apiece to raise $32M in gross proceeds. The company granted the underwriter a 30-day option to buy up to an additional 600K shares. Tela intends to use the net proceeds for working capital a...